following a resubmission assessed under the end of life and orphan medicine process:
axicabtagene cilocleucel (Yescarta®) is accepted for use within NHSScotland.
Indication under review: for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
In a randomised, open-label, phase III study in patients with relapsed or refractory DLBCL or HGBL, axicabtagene ciloleucel significantly improved event-free survival compared with standard of care.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- axicabtagene ciloleucel (Yescarta)
- SMC ID:
- SMC2695
- Indication:
Treatment of adult patients with diffuse large B‑cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 11 November 2024